|Bid||7.05 x 200|
|Ask||7.42 x 200|
|Day's Range||6.26 - 6.26|
|52 Week Range||4.60 - 7.49|
|PE Ratio (TTM)||-14.23|
|Earnings Date||Oct 30, 2017 - Nov 3, 2017|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||5.50|
NASHVILLE, Tenn. and BURTON ON TRENT, England, Sept. 25, 2017 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX, 'Cumberland') and Clinigen Group plc (AIM:CLIN, 'Clinigen'), announced today the promotional launch of Totect® (dexrazoxane hydrochloride), in the U.S. Totect is an FDA-approved hospital based emergency oncology intervention drug, indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications.
If you are a shareholder in Cumberland Pharmaceuticals Inc’s (NASDAQ:CPIX), or are thinking about investing in the company, knowing how it contributes to the risk and reward profile of yourRead More...
Q2 2017 Cumberland Pharmaceuticals Inc Earnings Call